Spyre Therapeutics, Inc. (SYRE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$96.59-2.47%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SYRE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Document Exhibit 99.1 Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKY…
Stated in 3 of 3 supplied quarters. Management reported: “Document Exhibit 99.1 Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”).” “SKYLINE Part B is enrolling ahead of schedule, enabling the Company to increase enrollment and provide topline induction results for three potential best-in-indication combinations, which are expected in Q3 2027 Reported positive topline results for SPY072 in rheumatoid arthritis (“RA”) sub-study of the Phase 2 SKYWAY basket trial (“SKYWAY”), though with a magnitude of benefit insufficient to prioritize advancement.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Document Exhibit 99.1 Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKY…”
“Document Exhibit 99.1 Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY001 and SPY002 from Part A of the…”
“Document Exhibit 99.1 Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial…”
Pro forma cash of $1,467.9 million as of September 30, 2026, with expected runway into the second half of 2029, also reflects $378.0 million in net proceeds from the recently closed October 2026 unde…
Stated in 3 of 3 supplied quarters. Management reported: “Pro forma cash of $1,467.9 million as of September 30, 2026, with expected runway into the second half of 2029, also reflects $378.0 million in net proceeds from the recently closed October 2026 underwritten public offering of common stock and $18.0 million in October 2026 at-the-market (ATM) sales.” “About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients.”
“Pro forma cash of $1,467.9 million as of September 30, 2026, with expected runway into the second half of 2029, also reflects $378.0 million in net proceeds from the recently closed October 2026 unde…”
“Document Exhibit 99.1 Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY001 and SPY002 from Part A of the…”
“Document Exhibit 99.1 Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial…”
• In Gastroenterology, the Company is advancing three potential first- and best-in-class combination programs in inflammatory bowel disease (“IBD”).
Stated in 3 of 3 supplied quarters. Management reported: “• In Gastroenterology, the Company is advancing three potential first- and best-in-class combination programs in inflammatory bowel disease (“IBD”).” “• The Company is currently enrolling its SPY120, SPY130, and SPY230 combinations in Part B of the SKYLINE trial, with an expected induction read-out in 2027.”
“• In Gastroenterology, the Company is advancing three potential first- and best-in-class combination programs in inflammatory bowel disease (“IBD”).”
“Rational Combinations [SPY120, SPY130 and SPY230] – the Company is investigating combinations of our proprietary antibodies in clinical trials in order to evaluate whether combinations can potentiall…”
“Rational Combinations – the Company plans to investigate combinations of our proprietary antibodies in nonclinical studies and clinical trials in order to evaluate whether combinations can potentiall…”
Continue development and data readouts of Phase 2 SKYLINE trial in IBD and SKYWAY basket trial in rheumatic diseases with six expected proof-of-concept readouts in 2026 and additional data in 2027.
Advance investigational extended half-life antibodies SPY001, SPY002, SPY003 for IBD and SPY072 for rheumatic diseases with focus on safety, efficacy, and combination potential.
Over the trailing year it converted 0.72x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.